Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration

Retina

Volumn 34, Issue 1, 2014, Pages 32-37

  Üney, Güner Ö ^a,b   Ünlü, Nurten ^a   Acar, Mehmet A ^a   Hazirolan, Dicle ^a   Altiparmak, Uǧur E ^a   Yalniz Akkaya, Zuleyha ^a   Örnek, Firdevs ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Göz Hastaliklari Kliniǧi ^*  (Turkey)

Author keywords

Age related macular degeneration; Anti vascular endothelial growth factor; Posterior vitreous detachment; Vitreomacular surface

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADHESION; AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PROGNOSIS; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS BODY DETACHMENT;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROGNOSIS; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS DETACHMENT; WET MACULAR DEGENERATION;

EID: 84891883779     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318295f72e     Document Type: Article

References (37)

1. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485.
2. Klein R, Klein BE, Lee KE, et al. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol 2006;142:539-549.
3. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol 2006;51:316-363.
4. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614.
5. Chakravarthy U, Augood C, Bentham GC, et al. Cigarette smoking and age-related macular degeneration in the EUREYE study. Ophthalmology 2007;114:1157-1163.
6. Krebs I, Brannath W, Glittenberg C, et al. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007;144:741-746.
7. Ondes F, Yilmaz G, Acar MA, et al. Role of the vitreous in age-related macular degeneration. Jpn J Ophthalmol 2000;44: 91-93.
8. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-1322.
9. Lee SJ, Koh HJ. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology 2011;118:101-110.
10. Spaide RF, Armstrong D, Browne R. Continuing medical education review: choroidal neovascularization in age-related macular degeneration-what is the cause? Retina 2003;23:595-614.
11. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-related eye disease study report no. 3. Ophthalmology 2000;107:2224-2232.
12. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389.
13. Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 2006;15:2955-2961.
14. Foos RY. Posterior vitreous detachment. Trans Am Acad Ophthalmol Otolaryngol 1972;76:480-497.
15. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004;242:690-698.
16. Robison CD, Krebs I, Bi{dotless}nder S, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol 2009;148:79-82.
17. Lee SJ, Lee CS, Koh HJ. Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study. Am J Ophthalmol 2009;147:621-626.
18. Weber-Krause B, Eckardt C. Incidence of posterior vitreous detachment in the elderly. Ophthalmologe 1997;94:619-623.
19. Lambert HM, Capone A Jr, Aaberg TM, et al. Surgical excision of subfoveal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992;113:257-262.
20. Schmidt-Erfurth U, Leitgeb RA, Michels S, et al. Threedimensional ultra-high-resolution optical coherence tomography of macular diseases. Invest Ophthalmol Vis Sci 2005;46:3393-3402.
21. Mojana F, Cheng L, Bartsch DU, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol 2008;146:218-227.
22. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-431.
23. Donoso LA, Kim D, Frost A, et al. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006;51:137-152.
24. Schubert HD. Cystoid macular edema: the apparent role of mechanical factors. Prog Clin Biol Res 1989;312:277-291.
25. Sebag J. Age-related differences in the human vitreo-retinal interface. Arch Ophthalmol 1991;109:966-971.
26. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004;242:91-101.
27. Rodrigues EB. Infammation in dry age-related macular degeneration. Ophthalmologica 2007;221:143-152.
28. Schulze S, Hoerle S, Mennel S, Kroll P. Vitreomacular traction and exudative age related macular degeneration. Acta Ophthalmol 2008;86:470-481.
29. Meyer CH, Toth CA. Retinal pigment epithelial tear with vitreomacular attachment: a novel pathogenic feature. Graefes Arch Clin Exp Ophthalmol 2001;239:325-333.
30. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147-163.
31. Tan LE, Orilla W, Hughes PM, et al. Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles. Invest Ophthalmol Vis Sci 2011;52:1111-1118.
32. Peeters L, Sanders NN, Braeckmans K, et al. Vitreous: a barrier to nonviral ocular gene therapy. Invest Ophthalmol Vis Sci 2005;46:3553-3561.
33. Pitkänen L, Ruponen M, Nieminen J, Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm Res 2003;20:576-583.
34. Worst JGF, Los LI. Functional Anatomy of the Vitreous. Cisternal Anatomy of the Vitreous. Amsterdam, the Netherlands: Kugler Publications; 1995:33-48.
35. Goldenberg DT, Giblin FJ, Cheng M, et al. Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. Retina 2011; 31:393-400.
36. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118.
37. Bringmann A, Pannicke T, Grosche J, et al. Müller cells in the healthy and diseased retina. Prog Retin Eye Res 2006;25: 397-424.